Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France

Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00812357

Acronym

SYMBIOSE

Enrollment

579

Registered

2008-12-22

Start date

2009-04-30

Completion date

2011-08-31

Last updated

2011-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Symbicort Turbuhaler, asthma, cohort study, France

Brief summary

Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Asthmatic patients treated for this disease with Symbicort Turbuhaler * Patients monitored for asthma by the doctor for at least 12 months * Patients seen in outpatient care at the baseline visit * Patients agreeing to participate in the study

Exclusion criteria

* Patients with any chronic lower respiratory disease other than asthma * Patients receiving anti-IgE agents in the last 4 months * Patients receiving desensitisation treatment outside of the maintenance phase * Patients deemed to be unable to respond to the study for linguistic or cognitive reasons

Design outcomes

Primary

Measure	Time frame
Level of control of the asthma	3 months
Evaluation of compliance with treatment	3 months

Countries

France

Outcome results